Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis
Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis
复制标题
DOI：
10.1007/s00296-007-0388-4
复制
发表时间：
2007-12-01
影响因子：
4
通讯作者：
Nagano, Akira
中科院分区：
文献类型：
--
作者：
Kageyama, Yasunori;Ichikawa, Tetsuya;Nagano, Akira
The purpose of this study was to analyze the effect of the soluble TNF-alpha receptor etanercept on the serum levels of IL-16, IL-17, IL-23, and macrophage inflammatory protein-3 alpha (MIP-3 alpha) in rheumatoid arthritis (RA) patients. Twenty-two patients with RA were administered etanercept once or twice a week for more than 6 months, and we evaluated clinical and laboratory parameters and serum levels of IL-16, IL-17, IL-23, and MIP-3 alpha at the baseline and at 3 and 6 months. Additionally, the production of IL-23 and MIP-3 alpha of cultured synovial cells stimulated with TNF-alpha from RA patients was determined by ELISA. We also used ELISA kits to determine synovial fluid (SF) levels of IL-17, IL-23, and MIP-3 alpha in patients with RA, osteoarthritis (OA), pseudogouty arthritis (PGA), and gouty arthritis (GA). A significant decrease in serum levels of IL-23 and MIP-3 alpha was observed at 3 and 6 months after initial treatment of etanercept. TNF-alpha induced MIP-3 alpha but not IL-23 production in cultured synovial cells from RA patients. SF levels of IL-17, IL-23, and MIP-3 alpha in RA patients showed significantly higher levels than those of OA, PGA, and GA patients. This study demonstrated that the reduction of IL-23 and MIP-3 alpha production in RA patients was a newly determined function of etanercept
